Clinical trial
MK-3475 as Maintenance Therapy in Extensive Stage SCLC
NCT02359019
Study timeline
Study start (unknown)2015-02-01Date precision: month
Registry last updated2022-10-14
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Interventions
PembrolizumabBIOLOGICAL
Sponsors & collaborators
Barbara Ann Karmanos Cancer Institutelead sponsor
National Cancer Institute (NCI)collaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02359019 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.